Hepatol Res:质子泵抑制剂治疗不会增加肝硬化患者血清内毒素水平

2018-09-27 MedSci MedSci原创

研究结果表明,PPI的使用并不会对肠道内毒素的血清水平产生重大影响,因为肝硬化患者的肠渗透率增加,内毒素水平已经升高了。

研究背景:肝硬化患者经常使用质子泵抑制剂(PPIs),但这种疗法可能会引起潜在并发症。本研究旨在调查PPI对肝硬化患者肠道渗透性的影响。

研究方法:本研究纳入228例肝硬化患者,将其分为4组。组1患者接受PPI和新霉素[PPI-NEO group; n = 14 (6.1%)],组2和组3患者或者接受PPI或者接受NEO [PPI组; n = 91 (39.9%), 和NEO 组; n = 11 (4.4%)],组4患者不接受药物治疗 [对照组; n = 112 (49.1%)]。采用内毒素活性 (EA) 来评估肠道渗透性。

研究结果:肝脏储备功能为B级的肝硬化患者,相比肝脏储备功能为A级的肝硬化患者,其内毒素活性显著增高;肝脏储备功能为C级的肝硬化患者和肝脏储备功能为A或B 级的肝硬化患者间,EA水平没有显著差异。在组1-4间,EA水平没有显著差异。203例不使用抗生素的患者包括91例接受PPI治疗的患者(Gp2)和112例未接受药物治疗的患者(Gp4),根据Child-Pugh(CP)分类进行细分。Gp2和Gp4之间,EA水平上没有显著的差异。

研究结论:研究结果表明,PPI的使用并不会对肠道内毒素的血清水平产生重大影响,因为肝硬化患者的肠渗透率增加,内毒素水平已经升高了。

原始出处


Okura Y, Namisaki T, Sato S, et al. Proton pump inhibitor therapy does not increase serum endotoxin activity in patients with cirrhosis. Hepatol Res, 2018,

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1704192, encodeId=c8f81e041929d, content=<a href='/topic/show?id=172330400dd' target=_blank style='color:#2F92EE;'>#内毒素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30400, encryptionId=172330400dd, topicName=内毒素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jun 09 11:33:00 CST 2019, time=2019-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851802, encodeId=ec771851802fe, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Jul 13 10:33:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667347, encodeId=0fde166e34758, content=<a href='/topic/show?id=03ab923565b' target=_blank style='color:#2F92EE;'>#质子泵#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92356, encryptionId=03ab923565b, topicName=质子泵)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=761326143554, createdName=shenxlcyp, createdTime=Wed Mar 13 07:33:00 CST 2019, time=2019-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427252, encodeId=f85d142e252f6, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Sep 29 12:33:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046343, encodeId=5701104634347, content=谢谢!最新的信息读起来就是收获大, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=guging, createdTime=Fri Sep 28 00:33:00 CST 2018, time=2018-09-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1704192, encodeId=c8f81e041929d, content=<a href='/topic/show?id=172330400dd' target=_blank style='color:#2F92EE;'>#内毒素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30400, encryptionId=172330400dd, topicName=内毒素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jun 09 11:33:00 CST 2019, time=2019-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851802, encodeId=ec771851802fe, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Jul 13 10:33:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667347, encodeId=0fde166e34758, content=<a href='/topic/show?id=03ab923565b' target=_blank style='color:#2F92EE;'>#质子泵#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92356, encryptionId=03ab923565b, topicName=质子泵)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=761326143554, createdName=shenxlcyp, createdTime=Wed Mar 13 07:33:00 CST 2019, time=2019-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427252, encodeId=f85d142e252f6, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Sep 29 12:33:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046343, encodeId=5701104634347, content=谢谢!最新的信息读起来就是收获大, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=guging, createdTime=Fri Sep 28 00:33:00 CST 2018, time=2018-09-28, status=1, ipAttribution=)]
    2019-07-13 jklm09
  3. [GetPortalCommentsPageByObjectIdResponse(id=1704192, encodeId=c8f81e041929d, content=<a href='/topic/show?id=172330400dd' target=_blank style='color:#2F92EE;'>#内毒素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30400, encryptionId=172330400dd, topicName=内毒素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jun 09 11:33:00 CST 2019, time=2019-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851802, encodeId=ec771851802fe, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Jul 13 10:33:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667347, encodeId=0fde166e34758, content=<a href='/topic/show?id=03ab923565b' target=_blank style='color:#2F92EE;'>#质子泵#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92356, encryptionId=03ab923565b, topicName=质子泵)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=761326143554, createdName=shenxlcyp, createdTime=Wed Mar 13 07:33:00 CST 2019, time=2019-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427252, encodeId=f85d142e252f6, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Sep 29 12:33:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046343, encodeId=5701104634347, content=谢谢!最新的信息读起来就是收获大, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=guging, createdTime=Fri Sep 28 00:33:00 CST 2018, time=2018-09-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1704192, encodeId=c8f81e041929d, content=<a href='/topic/show?id=172330400dd' target=_blank style='color:#2F92EE;'>#内毒素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30400, encryptionId=172330400dd, topicName=内毒素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jun 09 11:33:00 CST 2019, time=2019-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851802, encodeId=ec771851802fe, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Jul 13 10:33:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667347, encodeId=0fde166e34758, content=<a href='/topic/show?id=03ab923565b' target=_blank style='color:#2F92EE;'>#质子泵#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92356, encryptionId=03ab923565b, topicName=质子泵)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=761326143554, createdName=shenxlcyp, createdTime=Wed Mar 13 07:33:00 CST 2019, time=2019-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427252, encodeId=f85d142e252f6, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Sep 29 12:33:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046343, encodeId=5701104634347, content=谢谢!最新的信息读起来就是收获大, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=guging, createdTime=Fri Sep 28 00:33:00 CST 2018, time=2018-09-28, status=1, ipAttribution=)]
    2018-09-29 gwc384
  5. [GetPortalCommentsPageByObjectIdResponse(id=1704192, encodeId=c8f81e041929d, content=<a href='/topic/show?id=172330400dd' target=_blank style='color:#2F92EE;'>#内毒素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30400, encryptionId=172330400dd, topicName=内毒素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Sun Jun 09 11:33:00 CST 2019, time=2019-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851802, encodeId=ec771851802fe, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sat Jul 13 10:33:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667347, encodeId=0fde166e34758, content=<a href='/topic/show?id=03ab923565b' target=_blank style='color:#2F92EE;'>#质子泵#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92356, encryptionId=03ab923565b, topicName=质子泵)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=761326143554, createdName=shenxlcyp, createdTime=Wed Mar 13 07:33:00 CST 2019, time=2019-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427252, encodeId=f85d142e252f6, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Sep 29 12:33:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046343, encodeId=5701104634347, content=谢谢!最新的信息读起来就是收获大, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=guging, createdTime=Fri Sep 28 00:33:00 CST 2018, time=2018-09-28, status=1, ipAttribution=)]
    2018-09-28 guging

    谢谢!最新的信息读起来就是收获大

    0

相关资讯

Stroke:PPI与噻吩并吡啶

关于PPI和噻吩并吡啶交互作用的大部分研究多聚焦心血管事件,仅几项研究报道了脑血管事件。个别研究未能确定氯吡格雷联合PPI对缺血性卒中的影响。此外,由于缺乏证据(矛盾的结果),缺乏一致性意见,PPI联合噻吩并吡啶啶啶是临床的一道谜题。

当氯吡格雷,遇上质子泵抑制剂!

使用氯吡格雷,为何要联用质子泵抑制剂(PPIs)?

烧心?那些常见的质子泵抑制剂

质子泵抑制剂(PPIs)自上世纪80年代问世以来,对酸相关性疾病的治疗具有里程碑式的意义。通俗的讲,质子泵抑制剂就是指目前广泛用于治疗“烧心”相关症状的“拉唑”类药物。多种疾病,如消化性溃疡、幽门螺杆菌、卓-艾综合征(Zollinger-Ellison综合征)、胃食管反流病和上消化道出血等都会引起胃酸反流,引起“烧心”。

Stroke:质子泵抑制剂和噻氯吡啶类药物联合使用的脑血管结局!

由此可见,联合使用PPI和噻吩吡啶类药物会增加缺血性卒中和卒中/MI/心血管死亡复合事件发生风险。

Am J Gastroenterol:质子泵抑制剂可增加阿尔茨海默病风险?

发表于《Am J Gastroenterol》上的一项研究,考察了质子泵抑制剂的使用(PPI)和阿尔茨海默病(AD)风险之间的相关性。

质子泵抑制剂又“摊上事儿”了!

质子泵抑制(PPIs)最近几年已经被吐槽了好几回了,比如说肾损伤啊,心血管问题啊,脑血管问题啊,肺部感染啊,低镁血症啊,骨质疏松性骨折啊什么的……简直是被全身其他系统嫌弃了个遍!不过不管之前怎么被吐槽,它好歹还是个胃药吧……现在,研究发现,居然连胃也嫌弃它了!BMJ发表文章称,完成幽门螺杆菌治疗的患者,长期使用PPIs,会提高患胃癌的风险——这项研究还是在香港做的……可以说是量身为中国人打造了。研